Bendamustine and rituximab for indolent B-cell non-hodgkin lymphoma in patients with compensated hepatitis C cirrhosis: a case series

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):e15-7. doi: 10.1016/j.clml.2013.07.002. Epub 2013 Sep 20.

Authors

Stacey M Parker¹, Mustafa A Hyder, Mark J Fesler

Affiliation

¹ Division of Hematology and Oncology, Department of Internal Medicine, Saint Louis University, St Louis, MO.

PMID: 24060287
DOI: 10.1016/j.clml.2013.07.002

No abstract available

Keywords: Hepatic; Immunochemotherapy; Liver.

Publication types

Case Reports
Review

MeSH terms

Aged
Antibodies, Monoclonal, Murine-Derived / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride
Female
Hepatitis C, Chronic / complications*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Liver Cirrhosis / complications*
Liver Cirrhosis / etiology*
Lymphoma, B-Cell / complications*
Lymphoma, B-Cell / diagnosis
Lymphoma, B-Cell / drug therapy*
Lymphoma, Follicular / complications
Lymphoma, Follicular / drug therapy
Middle Aged
Nitrogen Mustard Compounds / administration & dosage
Rituximab
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Nitrogen Mustard Compounds
Rituximab
Bendamustine Hydrochloride